Vivekanand Yadav, PhD is a Research Investigator in the Dept. of Pediatrics, division of Hematology-Oncology at University of Michigan Medical School.
Dr. Yadav’s research focuses on understanding the underlying mechanisms central to the tumorigenesis of pediatric high-grade gliomas (pHGGs), particularly diffuse intrinsic pontine glioma (DIPG), an aggressive pediatric brain cancer with very poor prognosis.
The long-term goal of Dr.Yadav’s research is to understand the specific epigenetic dependencies and signaling pathways which arise as a consequence of the H3K27M mutation in pHGGs and identify promising candidates that can be targeted as therapy for the treatment of pHGGs, especially those with H3K27M or G34R mutations. He is currently working on identifying the role of ID1, a master transcription regulator in DIPG pathogenesis after identifying recently that the Id1 gene is epigenetically upregulated in human H3K27M-DIPG cells and that it drives invasion of DIPG cells. To capture the salient features of DIPG, like characteristic genetic alterations, anatomical location, and early development in a preclinical setting, Dr. Yadav have developed a robust genetically engineered mouse model of pediatric high-grade glioma (pHGG) with specific histone mutations (K27M or G34R glioma including DIPG and non-brainstem (NBSpHGG) tumors using in utero electroporation (IUE) technique. This model will help in targeted drug screening against actionable genetic alterations including tyrosine kinase inhibitors (TKIs), histone deacetylase inhibitors (HDIs), DNA-damage response inhibitors apart from testing checkpoint blockade immunotherapies.
2021 New Investigator Award from the Chad Tough Defeat DIPG Foundation.
2020 Faculty award for basic science research, Annual Pediatric Research Symposium for “Epigenetically activated ID1 is a key transcriptional regulator of DIPG Invasion and is targetable with cannabidiol”
Ongoing Research support
The ChadTough Defeat DIPG Foundation for the 'New Investigator Award"
Role: Principal investigator (PI)
Title: Epigenetically activated ID1 is a key transcriptional regulator of DIPG Invasion and is targetable with cannabidiol.
Chad Carr Pediatric Brain Tumor Center, University of Michigan
Role: Co-principal investigator (Co-PI)
Title: Therapeutic discovery in DIPG and pediatric high-grade glioma through a novel intra-uterine electroporation mouse model. (drug delivery/device development; immunotherapy)
Title: The role of ATRX mutation in the epigenetic dysregulation of cell cycle in pediatric high-grade glioma
Role: Co-investigator (Co-I)
Supporting Agency: R01, NIH
Contracting/Grants Officer: Performance Period: Level of Funding: $1,950,000
- Messinger M, Harris M K, Thomas C, Cummings J R, Yang T, Woo R, Siddaway R, Burkert M, Stallard S, Qin T, Mullan B, Siada R, Ravindran R, Niculcea M, Ginn KF, Gener M A.H., Dorris K, Vitanza NA, Schmidt S V, Spitzer J, Li J, Filbin M. G, Cao X, Castro MG, Lowenstein PR, Mody R, Chinnaiyan A, Desprez P, McAllister S, Hawkins C, Waszak SM, Venneti S, Koschmann C and Yadav VN*. Therapeutic reversal of prenatal pontine ID1 signaling in DIPG (In review, Neuro-Oncology) (*Senior authors).
- Qin T, Mullan B, Ravindran R, Siada R, Cummings J R, Harris M K, M Ashwath, Pyaram K, Miklja Z, Reiber M, Garcia T, Tran D, Danussi C , Brosnan-Cashman J, Pratt D, Zhao X, Rehemtulla A, Sartor A.M, Venneti S, Meeker A K, Huse J T, Morgan M A, Lowenstein P R, Castro M G, Yadav VN, Koschmann C. ATRX loss in glioma results in epigenetic dysregulation of cell cycle phase transition
(Under revision in Cell Reports.)
- Cantor E, Wierzbicki K, Tarapore R.S, Ravi K, Thomas C, Cartaxo R, Yadav VN, Ravindran R, Bruzek A K, Wadden J, Babila C M, Cummings J R, Kawakibi A. R, Ji S, Ramos J, Paul A, Walling D, Robertson P, Franson A, Mody R,. Garton H. J.L, Venneti S, Odia Y, Kline C, Vitanza NA, Khatua S, Mueller S, Allen
J.E., Gardner S, Koschmann C . Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. (Under revision in Neuro Oncology.)
- Stefan R. Sweha, Chan Chung, Siva Kumar Natarajan1, Pooja Panwalkar, Matthew Pun, Amer Ghali, Jill Bayliss, Drew Pratt, Anand Shankar, Visweswaran Ravikumar, Arvind Rao, Marcin Cieslik, Kari Wilder-Romans, Andrew J. Scott, Daniel R. Wahl, Selin Jessa, Claudia L. Kleinman, Nada Jabado, Alan Mackay, Chris Jones, Daniel Martinez, Mariarita Santi, Alexander R. Judkins, Viveka Nand Yadav, Tingting Qin, Timothy N. Phoenix, Carl J. Koschmann Suzanne J. Baker, Arul M. Chinnaiyan, Sriram Venneti. Epigenetically defined therapeutic targeting inH3G34R/V high-grade gliomas. Sci. Transl. Med. 13, eabf7860 (2021) 13 October 2021.
- Yadav VN*, Miklja Z*, Cartaxo R, Siada R, Thomas C, Cummings J, Mullan B, Stallard S, Paul A, Bruzek AK, Wierzbicki K, Yang T, Garcia T, Wolfe I, Parmar H, Leonard M, Robertson PL, Garton H, Wahl D, Sarkaria J, Kline C, Mueller S, Nicolades T, Glasser C, Leary S, Venneti S, Kumar-Sinha C, Chinnaiyan A, Mody R, Manjunath PP, Phoenix TN, Marini BL, Koschmann C* (2020). Everolimus improves the efficacy of dasatinib in the treatment of PDGFRA-driven glioma. J Clin Invest. 2020 Jun 30;doi: 10.1172/JCI133310. PMID: 32603316 (* Equal first author contribution)
- Chung C, Sweha S, Pratt D, Tamrazi B, Panwalkar P, Banda A, Bayliss J, Hawes D, Yang D, Lee HJ, Shan M, Cieslik M, Qin T, Werner C; Wahl D, Lyssiotis C, Bian Z, Shotwell J, Yadav VN, Koschmann C, Chinnaiyan A, Bluml S, Judkin A, Venneti S (2020). Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell. 2020 Jul 30:S1535-6108(20)30369-X
- Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E., Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C*. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma (2020). Curr Oncol Rep 2020 Feb: 22, 19
- Pyaram K* and Yadav VN* (2018) Advances in NKT cell Immunotherapy for Glioblastoma. J Cancer Sci Ther. 2018;10(6). pii: 533. (*co-senior authors).
- Yadav VN, Kadiyala P, Altshuler D, Zamler D, Patrick D, Koschmann C, Castro MG, Lowenstein PR (2018) Molecular ablation of tumor blood vessels inhibits therapeutic effects of radiation and anti-angiogenesis. Neuro-Oncology. 2018 Sep 3;20(10):1356-1367.
- Kumar J, Yadav VN, Phulera S, Kamble A, Gautam AK, Panwar HS, Sahu A. (2017) Species Specificity of Vaccinia Virus Complement Control Protein for the Bovine Classical Pathway Is Governed Primarily by Direct Interaction of Its Acidic Residues with Factor I. J Virol. 2017 Sep 12;91(19).
- Chandran M, Candolfi M, Shah D, Mineharu Y, Yadav VN, Koschmann C, Asad AS, Lowenstein PR, Castro MG (2017) Single vs. combination immunotherapeutic strategies for glioma. Expert Opin Biol Ther. 2017 May;17(5):543-554.
- Yadav VN, Zamler D, Baker GJ, Kadiyala P, Erdreich-Epstein A, DeCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR (2016) CXCR4 increases in-vivo glioma perivascular invasion, and reduces radiation induced apoptosis: A genetic knockdown study. Oncotarget. 2016 Dec 13;7(50):83701-83719.
- Calinescu AA, Yadav VN, Carballo E, Kadiyala P, Tran D, Zamler D, Doherty R, Srikanth M, Lowenstein PR, Castro MG (2016) Survival and proliferation of neural progenitor derived glioblastomas under hypoxic stress is controlled by a CXCL12/CXCR4 autocrine positive feedback mechanism. Clin Cancer Res. 2016 Aug 19. pii: clincanres.2888.2015.
- Kathania M, Zeng M, Yadav VN, Moghaddam SJ, Yang B, Venuprasad K. (2015) Ndfip1 regulates itch ligase activity and airway inflammation via UbcH7. J Immunol. 2015 Mar 1;194(5):2160-7.
- Baker GJ, Yadav VN, Motsch S, Koschmann C, Calinescu AA, Mineharu Y, Camelo-Piragua SI, Orringer D, Bannykh S, Nichols WS, deCarvalho AC, Mikkelsen T, Castro MG, Lowenstein PR. (2014) Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy. Neoplasia. 2014 Jul;16(7):543-61.
- Baker GJ, Chockley P, Yadav VN, Doherty R, Ritt M, Sivaramakrishnan S, Castro MG, Lowenstein PR (2014). Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. Cancer Res. 2014 Sep 15;74(18):5079-90.
- Lowenstein PR, Yadav VN, Chockley P, Castro M. (2014). There must be a way out of here: identifying a safe and efficient combination of promoter, transgene, and vector backbone for gene therapy of neurological disease. Mol Ther. 2014 Feb;22(2):246-7.
- Yadav VN, Pyaram K, Ahmad M and Sahu A. (2012) Species selectivity in poxviral complement regulators is dictated by the charge reversal in the central complement control protein modules. J. Immunol. 2012, 189(3): 1431-1439.
- Yadav VN, Pyaram K, Mullick J and Sahu A. (2008). Identification of hot spots in variola virus complement inhibitor (SPICE) for human complement regulation. J. Virol. 2008 82: 3283-3294.
- Pyaram K, Kieslich CA, Yadav VN, Morikis D and Sahu A (2010). Influence of electrostatics on the complement regulatory functions of Kaposica, the complement inhibitor of Kaposi’s sarcoma-associated herpesvirus. J. Immunol 2010. 184: 1956-1967.
- Pyaram K, Yadav VN, Reza MJ, and Sahu A (2010). Virus-complement interaction: an assiduous struggle for dominance. Future Virology 2010. 5: 709-730.
- Singh AK, Yadav VN, Pyaram K, Mullick J and Sahu A. (2009). Mapping of functional domains in herpesvirus saimiri complement control protein homolog: complement control protein domain 2 is the smallest structural unit displaying cofactor and decay-accelerating activities. J. Virol.2009 83: 10299-10304.
- Sreejith RK, Yadav VN, Varshney NK, Berwal SK, Suresh CG, Gaikwad SM, Pal JK (2009). Conformational characterization of human eukaryotic initiation factor 2α: A single tryptophan protein. Biochemica and Biophysica Res. Commun.2009 309: 273 -279.
- Mullick J, Singh AK, Bernet J, Yadav VN, and Sahu A (2004) Identification of Functional domains in Kaposica, the complement control protein homolog of Kaposi’s Sarcoma-Associated Herpes virus (Human herpesvirus 8) J. Virol.2004 79: 5850-5856.
Vivekanand Yadav (Vivek), PhD
3522 Medical Science Research Bldg. I
Dept. of Pediatrics-Hematology-Oncology
University of Michigan Medical School
Ann Arbor, MI 48109
Phone: 734 764-9860